-
News Buzz: Galapagos NV (NASDAQ:GLPG), OncoGenex Pharmaceuticals (NASDAQ:OGXI), Tornier N.V. (NASDAQ:TRNX), Alcatel Lucent SA (ADR) (NYSE:ALU), ConocoPhillips (NYSE:COP)
On Thursday shares of Galapagos NV (NASDAQ:GLPG) closed at $50.50. Galapagos NV (NASDAQ:GLPG) announced the pricing of its global offering totaling $275 million gross proceeds of 6550000 new ordinary shares consisting of 4996522 American Depositary Shares (“ADSs”) at $42.05 per ADS and 1533478 ordinary shares at a price of €37.00 per share both before underwriting…
-
Big Movers: OncoGenex Pharmaceuticals (NASDAQ:OGXI), Gevo (NASDAQ:GEVO), PGT (NASDAQ:PGTI), The New York Times Company (NYSE:NYT), NRG Yield (NYSE:NYLD)
On Monday shares of OncoGenex Pharmaceuticals, Inc. (NASDAQ:OGXI) closed at $1.78. Company’s sales growth for last 5 years was 1.20%. OncoGenex Pharmaceuticals, Inc. (NASDAQ:OGXI) announced that it will report its first quarter 2015 financial results on Thursday, May 14, 2015. Gevo, Inc. (NASDAQ:GEVO) in last trading activity fell -13.77% to close at $4.57. Company weekly…
-
Why Making Dramatic Moves: OncoGenex Pharmaceuticals (NASDAQ:OGXI), ImmunoCellular Therapeutics, (NYSEMKT:IMUC), Progenics Pharmaceuticals (NASDAQ:PGNX), Keurig Green Mountain (NASDAQ:GMCR), Eastman Chemical (NYSE:EMN)
On Friday shares of OncoGenex Pharmaceuticals, Inc. (NASDAQ:OGXI) closed at $1.90. Company’s sales growth for last 5 years was 1.20%. OncoGenex Pharmaceuticals, Inc. (NASDAQ:OGXI) announced that it will report its first quarter 2015 financial results on Thursday, May 14, 2015. ImmunoCellular Therapeutics, Ltd. (NYSEMKT:IMUC) in last trading activity advanced 1.09% to close at $0.46. Company…
-
Eye Catching Stocks: Aoxing Pharmaceutical Company (NYSEMKT:AXN), OncoGenex Pharmaceuticals (NASDAQ:OGXI), Sinclair Broadcast (NASDAQ:SBGI), Tremor Video (NYSE:TRMR), China Jo-Jo Drugstores (NASDAQ:CJJD)
On Wednesday shares of Aoxing Pharmaceutical Company, Inc. (NYSEMKT:AXN) closed at $1.70. Company’s sales growth for last 5 years was 7.40%. On April 27, Aoxing Pharmaceutical Company, Inc. (NYSEMKT:AXN) announced that the Company has received notification from the NYSE MKT that the Company is now back in compliance with the NYSE MKT’s continued listing standards…
-
Active Watch List: OSI Systems (NASDAQ:OSIS), Broadcom Corp. (NASDAQ:BRCM), OncoGenex Pharmaceuticals (NASDAQ:OGXI), Waddell & Reed Financial (NYSE:WDR), Expedia (NASDAQ:EXPE)
On Monday shares of OSI Systems, Inc. (NASDAQ:OSIS) closed at $69.73. Company’s sales growth for last 5 years was 9.00% and EPS growth for next 5 years is recorded as 18.00%. OSI Systems, Inc. (NASDAQ:OSIS) reported net income for the third quarter of $13.2 million, or $0.64 per share, compared to $4.8 million, or $0.23…
-
Hot Alert: OncoGenex Pharmaceuticals (NASDAQ:OGXI), SunEdison (NYSE:SUNE), Exxon Mobil Corporation (NYSE:XOM), Ericsson (NASDAQ:ERIC), Ennis Inc. (NYSE:EBF)
On Tuesday shares of OncoGenex Pharmaceuticals, Inc. (NASDAQ:OGXI) closed at $2.30. Company’s sales growth for last 5 years was 1.20%. Investment analysts at Needham & Company LLC cut their price objective on shares of OncoGenex Pharmaceuticals Inc (NASDAQ:OGXI) from $14.00 to $7.00 in a note issued to investors on Monday. The firm currently has a…
-
Why These Are Hot: OncoGenex Pharmaceuticals (NASDAQ:OGXI), Aemetis (NASDAQ:AMTX), Facebook Inc (NASDAQ:FB), Liberty Tax (NASDAQ:TAX), Foundation Medicine (NASDAQ:FMI)
OncoGenex Pharmaceuticals (NASDAQ:OGXI) has signed an agreement with Teva to regain rights to custirsen, now in phase 3 development. Custirsen blocks production of the protein clusterin, which may play a role in cell survival and treatment resistance in patients with prostate and lung cancers. By inhibiting clusterin, the drug could slow tumor growth to allow…
-
Active Movers: OncoGenex Pharmaceuticals (NASDAQ:OGXI), Chimerix (NASDAQ:CMRX), Cognizant Technology Solutions Corporation (NASDAQ:CTSH), Pilgrim’s Pride Corporation (NASDAQ:PPC), Entropic Communications (NASDAQ:ENTR)
On Feb. 24, OncoGenex Pharmaceuticals, Inc. (NASDAQ:OGXI) and Sarah Cannon announced that patient enrollment has been completed in the Spruce™ clinical trial, an investigator-sponsored, randomized, placebo-controlled Phase 2 trial evaluating apatorsen in combination with carboplatin and pemetrexed in patients with previously untreated, advanced, non-squamous, non-small cell lung cancer (NSCLC). Spruce is sponsored and led by…
-
Stocks News Alert: OncoGenex Pharmaceuticals (NASDAQ:OGXI), Hertz Global Holdings (NYSE:HTZ), Hercules Technology Growth Capital (NYSE:HTGC), Adamis Pharmaceuticals (NASDAQ:ADMP), JPMorgan Chase (NYSE:JPM)
On 24 February, OncoGenex Pharmaceuticals, Inc. (NASDAQ:OGXI) and Sarah Cannon announced that patient enrollment has been completed in the Spruce™ clinical trial, an investigator-sponsored, randomized, placebo-controlled Phase 2 trial evaluating apatorsen in combination with carboplatin and pemetrexed in patients with previously untreated, advanced, non-squamous, non-small cell lung cancer (NSCLC). On Tuesday shares of OncoGenex Pharmaceuticals,…
-
5 Active Stocks: Shake Shack Inc. (NYSE:SHAK), American International Group (NYSE:AIG), OncoGenex Pharmaceuticals (NASDAQ:OGXI), The Procter & Gamble (NYSE:PG), Halliburton (NYSE:HAL)
Shake Shack Inc. (NYSE:SHAK) opened two locations in the Boston area within the past week, including one on the city’s Newbury Street and one in Dedham. Boston Business Journal real estate editor Catherine Carlock joined necn to discuss what this means for the company’s future. On Monday shares Shake Shack Inc. (NYSE:SHAK) closed at $45.48.…